HBX 19,818

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571254

CAS#: NONE

Description: HBX 19,818 is a selective and irreversible USP7 inhibitor. HBX 19,818 has an IC50 of 28 μM In vivo activity for this compound has not yet been described.


Price and Availability

Size
Price

Size
Price

Size
Price

HBX 19,818 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 571254
Name: HBX 19,818
CAS#: NONE
Chemical Formula: C25H28ClN3O
Exact Mass: 421.1921
Molecular Weight: 421.97
Elemental Analysis: C, 71.16; H, 6.69; Cl, 8.40; N, 9.96; O, 3.79


Synonym: HBX 19,818; HBX-41,818; HBX41,818; HBX 41818; HBX-41818; HBX41818

IUPAC/Chemical Name: N-(3-(benzyl(methyl)amino)propyl)-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide

InChi Key: ZCALMLVWZSQGGR-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H28ClN3O/c1-29(17-18-8-3-2-4-9-18)15-7-14-27-25(30)19-12-13-23-21(16-19)24(26)20-10-5-6-11-22(20)28-23/h2-4,8-9,12-13,16H,5-7,10-11,14-15,17H2,1H3,(H,27,30)

SMILES Code: O=C(C1=CC=C(N=C(CCCC2)C2=C3Cl)C3=C1)N([H])CCCN(C)CC4=CC=CC=C4


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Ubiquitin specific protease 7 (USP7) supports cancer by positively affecting tumor growth and negatively affecting the patient’s immune response to tumors. USP7 inhibitors thus are an avenue of interest in potential cancer treatment. USP7 plays an important role in antagonizing p53 functions through multiple mechanisms. p53 is a critical tumor suppressor, and mutations in p53 are found in more than 50% of human cancers.


References

1: Wu J, Kumar S, Wang F, Wang H, Chen L, Arsenault P, Mattern M, Weinstock J. Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies. J Med Chem. 2017 Aug 18. doi: 10.1021/acs.jmedchem.7b00498. [Epub ahead of print] PubMed PMID: 28768102.